Eton Pharmaceuticals Inc.

2.96+0.0500+1.72%Vol 459.45K1Y Perf -52.14%
Jun 24th, 2022 16:00 DELAYED
BID2.93 ASK3.20
Open3.00 Previous Close2.91
Pre-Market- After-Market2.95
 - -  -0.01 -0.34%
Target Price
10.00 
Analyst Rating
Strong Buy 1.00
Potential %
237.84 
Finscreener Ranking
★★★     50.18
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★+     42.80
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★+     48.70
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Price Range Ratio 52W %
9.37 
Earnings Rating
Neutral
Market Cap74.66M 
Earnings Date
15th Aug 2022
Alpha-0.02 Standard Deviation0.15
Beta1.43 

Today's Price Range

2.953.16

52W Range

2.576.72

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.02%
1 Month
-8.64%
3 Months
-30.68%
6 Months
-30.52%
1 Year
-52.14%
3 Years
-59.34%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ETON2.960.05001.72
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
4.60
5.40
0.32
0.47
-22.90
Leverage Ratio 1.60
ProfitabilityValueIndustryS&P 500US Markets
85.50
-98.60
-94.60
-
-71.17
RevenueValueIndustryS&P 500US Markets
12.11M
0.48
155.21
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.08-0.21-162.50
Q04 20210.050.04-20.00
Q03 2021-0.14-0.24-71.43
Q02 2021-0.14-0.0842.86
Q01 20210.190.190.00
Q04 2020-0.26-0.32-23.08
Q03 2020-0.26-0.31-19.23
Q02 2020-0.28-0.2317.86
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.21-261.54Negative
9/2022 QR-0.03-121.43Negative
12/2022 FY-0.44--
12/2023 FY0.13--
Next Report Date15th Aug 2022
Estimated EPS Next Report-0.21
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume459.45K
Shares Outstanding25.22K
Shares Float23.98M
Trades Count2.05K
Dollar Volume1.42M
Avg. Volume79.29K
Avg. Weekly Volume59.28K
Avg. Monthly Volume67.48K
Avg. Quarterly Volume111.11K

Eton Pharmaceuticals Inc. (NASDAQ: ETON) stock closed at 2.96 per share at the end of the most recent trading day (a 1.72% change compared to the prior day closing price) with a volume of 459.45K shares and market capitalization of 74.66M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 17 people. Eton Pharmaceuticals Inc. CEO is Sean E. Brynjelsen.

The one-year performance of Eton Pharmaceuticals Inc. stock is -52.14%, while year-to-date (YTD) performance is -31%. ETON stock has a five-year performance of %. Its 52-week range is between 2.5711 and 6.72, which gives ETON stock a 52-week price range ratio of 9.37%

Eton Pharmaceuticals Inc. currently has a PE ratio of -6.00, a price-to-book (PB) ratio of 5.52, a price-to-sale (PS) ratio of 6.10, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -45.61%, a ROC of -51.99% and a ROE of -70.99%. The company’s profit margin is -71.17%, its EBITDA margin is -94.60%, and its revenue ttm is $12.11 Million , which makes it $0.48 revenue per share.

Of the last four earnings reports from Eton Pharmaceuticals Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Eton Pharmaceuticals Inc.’s next earnings report date is 15th Aug 2022.

The consensus rating of Wall Street analysts for Eton Pharmaceuticals Inc. is Strong Buy (1), with a target price of $10, which is +237.84% compared to the current price. The earnings rating for Eton Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eton Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eton Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 16.42, ATR14 : 0.18, CCI20 : 34.63, Chaikin Money Flow : -0.22, MACD : -0.10, Money Flow Index : 68.92, ROC : -1.33, RSI : 43.41, STOCH (14,3) : 66.04, STOCH RSI : 1.00, UO : 59.86, Williams %R : -33.96), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eton Pharmaceuticals Inc. in the last 12-months were: Sean E. Brynjelsen (Buy at a value of $43 200), W. Wilson Troutman (Buy at a value of $22 150)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eight product candidates in various stages of development.

CEO: Sean E. Brynjelsen

Telephone: +1 847 787-7361

Address: 21925 West Field Parkway, Deer Park 60010-7208, IL, US

Number of employees: 17

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

57%43%

Bearish Bullish

60%40%

TipRanks News for ETON

Tue, 22 Mar 2022 10:25 GMT Eton Pharmaceuticals (ETON) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

News

Stocktwits